Kamada Ltd (KMDA) stock

KMDANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 11, 2026Score 5/30

$8.09−0.04 (-0.49%)

Close on Nov 13, 2026Market cap $466.68MP/E –Yield –

Kamada ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Kamada's ebitda for the twelve months ending Jun 30, 2026 was $43.13M, up 8.0% year over year. For fiscal 2025 it was $41.15M, up 21.5% from the year before. The highest annual figure on record is $41.15M in fiscal 2025.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$41.15M	+21.5%
FY2024	Dec 31, 2024	$33.86M	+48.6%
FY2023	Dec 31, 2023	$22.78M	+36.5%
FY2022	Dec 31, 2022	$16.69M	+239.6%
FY2021	Dec 31, 2021	$4.91M	-79.6%
FY2020	Dec 31, 2020	$24.13M	-11.6%
FY2019	Dec 31, 2019	$27.30M	+18.9%
FY2018	Dec 31, 2018	$22.96M	+109.4%
FY2017	Dec 31, 2017	$10.97M	–
FY2016	Dec 31, 2016	-$1.98M	–
FY2015	Dec 31, 2015	-$8.20M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	$13.40M	+23.9%
Q1 FY2026	Mar 31, 2026	$10.80M	-5.3%
Q4 FY2025	Dec 31, 2025	$7.35M	-19.9%
Q3 FY2025	Sep 30, 2025	$11.58M	+35.6%
Q2 FY2025	Jun 30, 2025	$10.82M	+22.0%
Q1 FY2025	Mar 31, 2025	$11.41M	+56.8%
Q4 FY2024	Dec 31, 2024	$9.18M	+53.4%
Q3 FY2024	Sep 30, 2024	$8.54M	+13.1%
Q2 FY2024	Jun 30, 2024	$8.87M	+52.0%
Q1 FY2024	Mar 31, 2024	$7.28M	+213147.4%
Q4 FY2023	Dec 31, 2023	$5.98M	-64.1%
Q3 FY2023	Sep 30, 2023	$7.55M	+134260.0%
Q2 FY2023	Jun 30, 2023	$5.84M	+660.8%
Q1 FY2023	Mar 31, 2023	$3.41K	-99.9%
Q4 FY2022	Dec 31, 2022	$16.68M	–
Q3 FY2022	Sep 30, 2022	$5.62K	-98.7%
Q2 FY2022	Jun 30, 2022	$767.00K	-66.2%
Q1 FY2022	Mar 31, 2022	$3.27M	-16.4%
Q4 FY2021	Dec 31, 2021	-$1.31M	-114.5%
Q3 FY2021	Sep 30, 2021	$436.00K	–
Q2 FY2021	Jun 30, 2021	$2.27M	–
Q4 FY2020	Dec 31, 2020	$3.91M	–
Q3 FY2020	Sep 30, 2020	$9.02M	–